Clinical Trial Update: Inhibition of Anaphylaxis by Ibrutinib [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ibrutinib for inhibition of anaphylaxis in food allergy has completed, with results posted on 2025-01-17.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaphylaxis
• Food Allergy

Drugs mentioned

• Ibrutinib (Imbruvica) (Ibrutinib)

Snippet

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago | Conditions: Food Allergy, Anaphylaxis Food | Phase 2 | Status: COMPLETED | Results posted: 2025-01-17